Opinion|Videos|January 24, 2024
Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines
Allison Wheeler, MD, explores the transformative journey of hemophilia A treatment, from blood products to advanced recombinant factor therapies, longer half-life products, and subcutaneous injections, that have revolutionized care.
Episodes in this series
This is a video synopsis/summary of an Insights involving Allison Wheeler, MD.
Wheeler reflects on the remarkable evolution of hemophilia A treatment over the past decade, emphasizing the shift from blood products to advanced therapies. She notes the progression from whole blood and plasma to concentrated products, including recombinant factor products produced in individual cell lines. The recent innovations, such as factor VIII memetic and extended half-life products, offer improved prophylactic options, allowing patients greater flexibility and reducing bleeding events. This transformative landscape has significantly impacted clinical decision-making.
When discussing treatment guidelines, Wheeler acknowledges the valuable recommendations from various organizations like the Medical and Scientific Advisory Council, American Society of Hematology, International Society on Thrombosis and Haemostasis, and the World Hemophilia Foundation. She underscores the collaborative effort of these entities in adapting to the era of innovation. While guidelines play a crucial role, Wheeler highlights the importance of individualized care, emphasizing how the multitude of treatment options empowers clinicians to tailor approaches based on each patient’s unique needs. This patient-centric approach, coupled with adherence to guidelines, contributes to enhanced care outcomes in the evolving hemophilia A treatment landscape.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Related to this article
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
These findings demonstrate substantial but variable use of community care consultations for specialty care among patients with diabetic foot ulcers within the Veterans Health Administration.
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
Trending on AJMC
1
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Switching to Subcutaneous Ocrelizumab for MS Could Free 883 Chair Hours in a Year
4
Why 4 in 5 Eligible Adults Miss Lung Cancer Screening
5